Retina and Glaucoma Experts Will Present Best Practices Using Iridex Technologies at a Consensus Panel and the AAO Annual Meeting
On November 6, 2021, Iridex Corporation (NASDAQ: IRIX) will host an international expert consensus panel discussing MicroPulse Transscleral Laser Therapy (TLT). The panel aims to provide insights on dosing and patient selection for better treatment outcomes. Key points include fluence, sweep speed, and drivers for patient selection. This event aligns with the upcoming American Academy of Ophthalmology meeting from November 13-15, where Iridex will showcase its innovations and host experts for discussions on the effectiveness of laser therapies for glaucoma and retinal diseases.
- International consensus panel will enhance understanding of MicroPulse TLT.
- Increased focus on best practices may lead to improved patient outcomes.
- Presence at AAO meeting provides significant exposure to industry experts and potential customers.
- None.
An international expert consensus panel will discuss best practices in dosing and patient selection using MicroPulse TLT on November 6, 2021
Panel members scheduled for discussions at the Iridex booth during AAO meeting on November 13-15th
MOUNTAIN VIEW, Calif., Nov. 06, 2021 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, announces that an international consensus panel of ten glaucoma experts will discuss MicroPulse Transscleral Laser Therapy and their conclusions for proper dosing and patient selection on November 6 at 10:00am PT/ 1:00pm ET. In the live discussion, attendees will learn recommendations for treatment optimization and settings with the MicroPulse P3® Probe, understand the concept of fluence and the importance of sweep speed, as well as identify the clinical drivers for patient selection, outcomes, and safety.
“As MicroPulse TLT emerges as a key tool in the management of glaucoma, this panel convened to execute a complete analysis of the clinical, technical, practical evidence and experience to date with the MicroPulse P3 and created a consensus document with recommendations for the worldwide clinical application of MicroPulse TLT,” said Tomas Grippo, MD. “Our findings will help providers understand the concept of fluence and the importance of sweep speed, as well as identify the most important clinical drivers for patient selection, outcomes, and safety.”
To learn more about the discussion and consensus panel, visit www.iridex.com/consensus
Iridex at AAO
Iridex will present its products and services at the upcoming American Academy of Ophthalmology November 13-15th in New Orleans, LA and will feature opportunities for attendees to meet with glaucoma and retinal physicians from around the world who are experts in the use and application of Iridex lasers. Opportunities include:
Lasers and Latte
Join Iridex on Saturday, November 13 from 10:00AM – 4:00PM and Sunday, November 14 from 11:00AM – 4:00PM at booth #844
This is an excellent opportunity to ask experts questions and better understand the safety, efficacy, durability, and versatility of the various procedures performed with lasers to treat glaucoma and retinal diseases. Nineteen laser experts, including Robert J. Noecker, MD; Brian A. Francis, MD; Sam E. Mansour, MD; and Nathan Radcliffe, MD, will be available to discuss experiences, surgical pearls and best practices. To find out specific times and available experts, visit https://www.iridex.com/aao
Skills Transfer Lab
Sunday, November 14, from 10:30 AM - 12:30 PM in the glaucoma lab (room 353 - 355).
Two Iridex glaucoma procedures, MicroPulse Transscleral Laser Therapy and Continuous Wave Transscleral Cyclophotocoagulation, will be featured in one of AAO's Skills Transfer Labs. The title of the course is "Lasers in Glaucoma," and its director will be Lisa S. Gamell, MD. This course is part of the AAO program; participation requires an AAO registration. The course number is LAB128A
About Iridex
Iridex is a worldwide leader in developing innovative and versatile laser-based medical systems, delivery devices, and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers a differentiated treatment that provides safe, effective, and proven therapy for targeted sight-threatening eye conditions. Iridex’s products are used to treat glaucoma, diabetic macular edema, and other retinal diseases. Iridex products are sold in the United States and Germany through a direct sales force and in more than 100 countries through a network of independent distributors. For more information, visit www.iridex.com.
Iridex Media Contact
Jamie Hall
Pascale Communications, LLC.
(724) 417-0167
jamie@pascalecommunications.com
FAQ
What is the purpose of the expert panel discussion hosted by Iridex on November 6, 2021?
Where will Iridex showcase its products and services in November 2021?
What topics will be covered during the Iridex panel discussion?
Who are some of the experts participating in the Iridex events at AAO?
How can I learn more about the Iridex consensus panel?
